Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells
1997

Glutathione-Doxorubicin Conjugate and Its Potent Cytotoxicity

publication Evidence: moderate

Author Information

Author(s): T Asakura, K Ohkawa, N Takahashi, K Takada, T Inoue, S Yokoyama

Primary Institution: Jikei University School of Medicine

Hypothesis

The study investigates the cytotoxic mechanism of a conjugate of doxorubicin and glutathione in rat hepatoma cells.

Conclusion

The glutathione-doxorubicin conjugate exhibits potent cytotoxicity by inhibiting glutathione S-transferase activity.

Supporting Evidence

  • GSH-DXR showed non-competitive inhibition of GST activity with an IC50 value of 1.3 µM.
  • Substituting amino acids for cysteine in GSH reduced cytotoxicity by two- to fourfold.
  • Treatment with tributyltin acetate significantly increased cytotoxicity of GSH-DXR.

Takeaway

A special drug made by combining doxorubicin and glutathione can kill cancer cells better than doxorubicin alone.

Methodology

The study used rat hepatoma cell lines to compare the cytotoxic effects of doxorubicin and its conjugate with glutathione.

Participant Demographics

Rat hepatoma cells (AH66P and AH66DR).

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication